Symbols / TRAW Stock $1.62 +1.89% Traws Pharma, Inc.

Healthcare • Biotechnology • United States • NCM
TRAW (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Iain D. Dukes DPHIL, M.A., Ph.D.
Exch · Country NCM · United States
Market Cap 24.54M
Enterprise Value 20.96M
Income -13.91M
Sales 2.73M
FCF (ttm) -10.82M
Book/sh -0.07
Cash/sh 0.21
Employees 4
Insider 10d —
IPO Jul 25, 2013
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 1.98
Forward P/E -0.40
PEG —
P/S 8.98
P/B -23.48
P/C —
EV/EBITDA -1.07
EV/Sales 7.67
Quick Ratio 0.36
Current Ratio 0.43
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 0.82
EPS next Y -4.03
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-05-15
ROA -90.09%
ROE -56.39%
ROIC —
Gross Margin 100.00%
Oper. Margin -7.18%
Profit Margin 0.00%
Shs Outstand 15.15M
Shs Float 8.00M
Insider Own 10.46%
Instit Own 29.79%
Short Float 4.50%
Short Ratio 2.26
Short Interest 560.04K
52W High 3.27
vs 52W High -50.46%
52W Low 1.00
vs 52W Low 62.00%
Beta —
Impl. Vol. —
Rel Volume 0.43
Avg Volume 2.16M
Volume 935.41K
Target (mean) $5.50
Tgt Median $5.50
Tgt Low $3.00
Tgt High $8.00
# Analysts 2
Recom Strong_buy
Prev Close $1.59
Price $1.62
Change 1.89%
About

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.50
Mean price target
2. Current target
$1.62
Latest analyst target
3. DCF / Fair value
$-12.86
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.62
Low
$3.00
High
$8.00
Mean
$5.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-20 reit HC Wainwright & Co. Buy → Buy $8
2025-12-03 init HC Wainwright & Co. — → Buy $8
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 597,729 $1.21 $723,252
2025-12-12 STOVER JACK E Director — 6,157 $0.00 $0
2025-12-12 LEAMAN JOHN HAROLD Director — 4,058 $0.00 $0
2025-12-12 DUKES IAIN D Chief Executive Officer — 36,943 $0.00 $0
2025-12-12 SHOEMAKER MARY TERESA Director — 6,157 $0.00 $0
2025-12-12 CLARKE TRAFFORD PH.D. Director — 6,157 $0.00 $0
2025-12-12 PAUZA CHARLES DAVID Officer — 18,471 $0.00 $0
2025-12-12 CAUTREELS WERNER C Director — 4,874 $0.00 $0
2025-12-12 REDFIELD ROBERT Officer — 16,419 $0.00 $0
2025-12-12 SAVCHUK NIKOLAY Chief Operating Officer — 16,419 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
2.79
+1134.51%
0.23
+0.00%
0.23
+0.00%
0.23
Operating Revenue
2.79
+1134.51%
0.23
+0.00%
0.23
+0.00%
0.23
Operating Expense
20.66
-17.79%
25.14
+22.47%
20.52
+3.38%
19.85
Research And Development
12.14
-5.48%
12.85
+12.40%
11.43
+0.21%
11.41
Selling General And Administration
8.52
-30.65%
12.29
+35.13%
9.09
+7.66%
8.45
General And Administrative Expense
8.52
-30.65%
12.29
+35.13%
9.09
+7.66%
8.45
Salaries And Wages
3.06
-27.87%
4.24
+6.66%
3.98
+0.84%
3.95
Other Gand A
4.62
-35.64%
7.18
+73.97%
4.13
+28.82%
3.21
Total Expenses
20.66
-17.79%
25.14
+22.47%
20.52
+3.38%
19.85
Operating Income
-17.88
+28.24%
-24.91
-22.72%
-20.30
-3.42%
-19.63
Total Operating Income As Reported
-17.88
+87.45%
-142.37
-601.42%
-20.30
-3.42%
-19.63
EBITDA
-17.81
+28.45%
-24.90
-22.76%
-20.28
-3.41%
-19.61
Normalized EBITDA
-44.38
-137.93%
117.00
+676.89%
-20.28
-3.41%
-19.61
Reconciled Depreciation
0.06
+408.33%
0.01
-25.00%
0.02
+14.29%
0.01
EBIT
-17.88
+28.24%
-24.91
-22.72%
-20.30
-3.42%
-19.63
Total Unusual Items
26.57
+118.72%
-141.90
0.00
—
Total Unusual Items Excluding Goodwill
26.57
+118.72%
-141.90
0.00
—
Special Income Charges
0.00
+100.00%
-117.46
0.00
—
Other Special Charges
—
117.46
—
—
Net Income
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Pretax Income
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Other Income Expense
27.05
+119.10%
-141.61
-10589.85%
1.35
+103.62%
0.66
Other Non Operating Income Expenses
0.48
+65.40%
0.29
-78.59%
1.35
+103.62%
0.66
Gain On Sale Of Security
26.57
+208.71%
-24.44
—
—
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Net Income From Continuing Operation Net Minority Interest
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Net Income From Continuing And Discontinued Operation
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Net Income Continuous Operations
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Normalized Income
-17.40
+29.34%
-24.62
-29.94%
-18.95
+0.08%
-18.96
Net Income Common Stockholders
6.87
+112.56%
-54.67
-188.55%
-18.95
+0.08%
-18.96
Diluted EPS
0.82
+102.33%
-35.21
-56.00%
-22.57
+0.79%
-22.75
Basic EPS
0.83
+102.36%
-35.21
-56.00%
-22.57
+0.79%
-22.75
Basic Average Shares
8.23
+429.93%
1.55
+84.94%
0.84
+0.39%
0.84
Diluted Average Shares
8.38
+439.48%
1.55
+84.94%
0.84
+0.39%
0.84
Diluted NI Availto Com Stockholders
6.87
+112.56%
-54.67
-188.55%
-18.95
+0.08%
-18.96
Insurance And Claims
0.84
-2.67%
0.86
-12.69%
0.98
-23.94%
1.29
Preferred Stock Dividends
2.31
+102.06%
-111.85
—
—
Line Item Trend 2023-12-31
Total Assets
22.68
Current Assets
22.66
Cash Cash Equivalents And Short Term Investments
20.82
Cash And Cash Equivalents
20.82
Receivables
0.02
Accounts Receivable
0.02
Prepaid Assets
1.42
Other Current Assets
0.40
Total Non Current Assets
0.02
Net PPE
0.02
Gross PPE
0.08
Accumulated Depreciation
-0.06
Machinery Furniture Equipment
0.08
Goodwill And Other Intangible Assets
—
Other Intangible Assets
—
Other Non Current Assets
0.00
Total Liabilities Net Minority Interest
12.01
Current Liabilities
9.22
Payables And Accrued Expenses
7.99
Payables
5.62
Accounts Payable
5.62
Current Accrued Expenses
2.37
Pensionand Other Post Retirement Benefit Plans Current
1.00
Current Deferred Liabilities
0.23
Current Deferred Revenue
0.23
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
2.79
Non Current Deferred Liabilities
2.79
Non Current Deferred Revenue
2.79
Stockholders Equity
10.67
Common Stock Equity
10.67
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
0.84
Ordinary Shares Number
0.84
Treasury Shares Number
0.00
Additional Paid In Capital
493.32
Retained Earnings
-482.63
Gains Losses Not Affecting Retained Earnings
-0.02
Other Equity Adjustments
-0.02
Total Equity Gross Minority Interest
10.67
Total Capitalization
10.67
Working Capital
13.44
Invested Capital
10.67
Net Tangible Assets
10.67
Tangible Book Value
10.67
Derivative Product Liabilities
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-18.18
+38.96%
-29.79
-66.14%
-17.93
-10.05%
-16.29
Cash Flow From Continuing Operating Activities
-18.18
+38.96%
-29.79
-66.14%
-17.93
-10.05%
-16.29
Net Income From Continuing Operations
9.17
+105.51%
-166.52
-778.84%
-18.95
+0.08%
-18.96
Depreciation Amortization Depletion
0.06
+408.33%
0.01
-25.00%
0.02
+14.29%
0.01
Depreciation And Amortization
0.06
+408.33%
0.01
-25.00%
0.02
+14.29%
0.01
Other Non Cash Items
—
117.46
—
—
Stock Based Compensation
0.73
-47.63%
1.39
+6.84%
1.30
+11.01%
1.17
Operating Gains Losses
-26.57
-208.71%
24.44
—
—
Gain Loss On Investment Securities
-26.57
-208.71%
24.44
—
—
Change In Working Capital
-1.58
+76.01%
-6.57
-2083.72%
-0.30
-120.28%
1.48
Change In Receivables
-2.03
-16.14%
-1.75
-15981.82%
0.01
+1200.00%
-0.00
Change In Prepaid Assets
1.48
+5592.59%
-0.03
+97.86%
-1.26
-450.22%
-0.23
Change In Payables And Accrued Expense
1.76
+138.49%
-4.57
-489.52%
1.17
-39.20%
1.93
Change In Accrued Expense
2.37
+145.45%
-5.22
-792.14%
-0.58
-170.65%
0.83
Change In Payable
-0.61
-194.74%
0.65
-63.27%
1.76
+59.47%
1.10
Change In Account Payable
-0.61
-194.74%
0.65
-63.27%
1.76
+59.47%
1.10
Change In Other Working Capital
-2.79
-1134.96%
-0.23
+0.00%
-0.23
+0.00%
-0.23
Change In Other Current Assets
—
—
0.00
-100.00%
0.01
Investing Cash Flow
-2.58
+29.14%
-3.65
-25957.14%
-0.01
0.00
Cash Flow From Continuing Investing Activities
-2.58
+29.14%
-3.65
-25957.14%
-0.01
0.00
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.01
0.00
Purchase Of PPE
—
0.00
+100.00%
-0.01
0.00
Capital Expenditure
-2.58
—
-0.01
—
Net Business Purchase And Sale
0.00
+100.00%
-3.65
0.00
—
Purchase Of Business
0.00
+100.00%
-3.65
0.00
—
Net Intangibles Purchase And Sale
-2.58
0.00
—
—
Purchase Of Intangibles
-2.58
0.00
—
—
Financing Cash Flow
3.20
-90.57%
33.98
0.00
0.00
Cash Flow From Continuing Financing Activities
3.20
-90.57%
33.98
0.00
0.00
Net Common Stock Issuance
5.58
-83.57%
33.98
0.00
0.00
Proceeds From Stock Option Exercised
0.03
0.00
—
0.00
Net Other Financing Charges
-2.40
—
—
—
Changes In Cash
-17.57
-3377.24%
0.54
+102.99%
-17.95
-10.14%
-16.29
Effect Of Exchange Rate Changes
0.05
+352.63%
-0.02
-290.00%
0.01
+152.63%
-0.02
Beginning Cash Position
21.34
+2.48%
20.82
-46.28%
38.76
-29.62%
55.07
End Cash Position
3.82
-82.10%
21.34
+2.48%
20.82
-46.28%
38.76
Free Cash Flow
-20.77
+30.28%
-29.79
-66.01%
-17.95
-10.14%
-16.29
Common Stock Issuance
5.58
-83.57%
33.98
0.00
0.00
Issuance Of Capital Stock
5.58
-83.57%
33.98
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category